Janssen Pharmaceuticals and its development partner Bayer announced results of two new real-world studies, which  confirmed the positive benefit-risk profile of XARELTO (rivaroxaban) in treating venous thromboembolism (VTE), or blood clots, and minimising the risk of recurrence.

One study indicated that people with VTE taking XARELTO for longer than three months had a lower risk of VTE recurrence, without an increase in major bleeding, compared to those taking the medicine for only three months.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The second was the first read-out from Janssen's Post-Marketing Safety Surveillance (PMSS) study in VTE, which indicated the rates and patterns of major bleeding in people taking XARELTO for VTE in routine clinical practice were consistent with those reported in clinical trials.

VTE is a collective term, including deep vein thrombosis (DVT), a blood clot in a deep vein (usually the leg), and pulmonary embolism (PE), when a clot travels to the lung.

"VTE impacts more than 900,000 people each year in the US, and one-third of these occurrences will be fatal."

VTE impacts more than 900,000 people each year in the US, and one-third of these occurrences will be fatal.

See Also:

Once a person experiences VTE, they are at an increased risk of it occurring again.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

XARELTO is a prescription medicine used to cut down the risk of stroke and blood clots in people with atrial fibrillation, not caused by a heart valve problem. For those patients who are currently well managed on warfarin, there is limited information on how XARELTO and warfarin compare in reducing the risk of stroke.

It is also used to treat deep vein thrombosis and pulmonary embolism, and to help cut down the risk of these conditions occurring again.

XARELTO is additionally a prescription medicine for reducing the risk of forming a blood clot in the legs and lungs of people who have just had knee or hip replacement surgery.